Durable clinical and pathologic response of hepatocellular carcinoma to systemic and hepatic arterial administration of platinol, recombinant interferon α 2B, doxorubicin, and 5-fluorouracil: A communication

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 22, Issue 2, 1999, Pages 209-213

  Patt, Yehuda Z ^a,b   Hoque, Ashraful ^a   Roh, Mark ^a   Ellis, Lee ^a   Lozano, Richard ^a   Carrasco, Cesar H ^a   Charnsangavej, Chulsip ^a   Cleary, Karen ^a  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

5 Fluorouracil; Chemobiotherapy; Doxorubicin; Hepatocellular carcinoma; PIAF; Platinol; Recombinant interferon 2b

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; ALPHA FETOPROTEIN; AMIFOSTINE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; DOXORUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; LACTATE DEHYDROGENASE; RECOMBINANT ALPHA2B INTERFERON;

AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DEHYDRATION; ECHOGRAPHY; FEMALE; HUMAN; LIVER CELL CARCINOMA; LUNG METASTASIS; MUCOSA INFLAMMATION; NEPHROTOXICITY; STOMATITIS;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CISPLATIN; DOXORUBICIN; FEMALE; FLUOROURACIL; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; INTERFERON ALFA-2B; LIVER NEOPLASMS;

EID: 0033497580     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199904000-00024     Document Type: Article

References (32)

1. Ihde DC, Kane RC, Cohen MH, McIntire KR. Minna JD. Adriamycin therapy in American patients with hepatocellular carcinoma. Cancer Treat Rep 1977;61:1385-7.
2. Vogel CL, Baley AC, Brooker RJ. Anthony PP. Ziegler JL. A phase II study of Adriamycin (NSC 123127) in patients with hepatocellular carcinoma from Zambia and the United States. Cancer 1977;39:1923-9.
3. Falkson G, Moertel CG, LaVin P, Pretorias FJ, Carbone PP. Chemotherapy studies in primary liver cancer. Cancer 1978;42: 2149-56.
4. Melia WM, Johnson PJ. Williams R. Induction of remission in hepatocellular carcinoma: a comparison of VP-16 with Adriamycin. Cancer 1983;51:206-10.
5. Sciarrino E, Simonetti RG. LeMoli S, Pagliaro L. Adriamycin treatment for hepatocellular carcinoma. Experience with 109 patients. Cancer 1985;56:2751-5.
6. Lai C-L, Wu P-C, Chan CG-B. Lok AS, Lin HJ. Doxorubicin versus no antitumor therapy in inoperable, hepatocellular carcinoma: a prospective randomized trial. Cancer 1988;62:479-83.
7. Brennan M, Talley R, Sandiego E. Critical analysis of 594 cancer patients treated with 5-fluorouracil. In: Plattner A, ed. Proceedings, International Symposium on Chemotherapy. New York: Elsevier, 1964:118-50.
8. Davis HL Jr, Ramirez G, Ansfield FJ. Adenocarcinoma of stomach, pancreas, liver and biliary tracts: survival of 328 patients treated with fluoropyrimidine therapy. Cancer 1974;33:193-7.
9. Gailani S, Holland J, Falkson G, Leone L, Burningham R. Larsen V, Comparison of treatment of metastatic gastrointestinal cancer with 5-fluorouracil (5FU) to a combination of 5FU with cytosine arabinoside. Cancer 1972;29:1308-13.
10. Ravry M, Omura G. Bartolucci AA. Einhorn L, Kramer B, Davila E. Phase II evaluation of cisplatin in advanced hepatocellular carcinoma and cholangiocarcinoma: a Southeastern Cancer Study Group trial. Cancer Treat Rep 1986;70:311-2.
11. Okada S, Okazaki N, Nose H, Shimada Y, Yoshimori M, Aoki K. A phase 2 study of cisplatin in patients with hepatocellular carcinoma. Oncology 1993;50:22-6.
12. Lai CL, Lau JY, Wu PC, et al. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology 1993;17:389-94.
13. Lai CL, Wu PC, Lok AS. et al. Recombinant alpha-2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomized trial. Br J Cancer 1989;60:928-33.
14. Vernook AP. Treatment of hepatocellular carcinoma: too many options? J Clin Oncol 1994;12:1323-34.
15. Andersson M, Aronsen KF, Balch C. et al. Pharmaco-kinetics of intra-arterial mitomycin-C with or without degradable starch microspheres (DSM) in the treatment of non-resectable liver cancer. Acta Oncol 1989;28:219-22.
16. Pan YZ, Chuang VP, Wallace S, Benjamin RS, Fuqua R, Mavligit GM. Hepatic arterial chemotherapy and occlusion for palliation of primary hepatocellular and unknown primary neoplasms in the liver. Cancer 1983;51:1359-63.
17. Patt YZ, Charnsangavej C, Yoffe B, et al. Hepatic arterial infusion of floxuridine, leucovorin, doxorubicin, and cisplatin for hepatocellular carcinoma: effects of hepatitis B and C viral infection on drug toxicity and patient survival. J Clin Oncol 1994;12:1204-11.
18. Fukushima H, Hirai K, Shimada M, et al. Hepatocellular carcinoma with a complete remission of bone metastasis achieved by arterial chemotherapy. Can No Rinsho 1990;36:2059-62.
19. Kobayashi T, Yoshida M, Araki I, et al. A resected case of hepatocellular carcinoma effectively treated by hepatic artery embolization and systemic chemotherapy. Can To Kagaku Ryoho 1989;16:3791-4.
20. Urabe T, Mizuno Y, Terada M, et al. A case with hepatocellular carcinoma with complete remission due to gamma-IFN therapy. Nippon Gan Chiryo Gakkai Shi 1989;24:1616-22.
21. Buchanan TF, Huvos AG. Clear-cell carcinoma of the liver: a clinicopathologic study of 13 patients. Am J Clin Pathol 1974;61: 529-39.
22. Schwartz EL, Hoffman LM. O'Connor CJ. Wadler S. Stimulation of 5 fluorouracil metabolic activation by interferon-a in human colon cancer cells. Biochem Biophys Res Commun 1992;182: 1232-9.
23. Elias L, Sandoval JM. Interferon effects upon fluorouracil metabolism by HL-60 cells. Biochem Biophys Res Commun 1989;163: 867-74.
24. Krebser ED, Wadler S, Thiel E. Biochemical modulation of cytotoxic drugs by cytokines: molecular mechanisms in experimental oncology. Recent Results Cancer Res 1995;139:371-82.
25. Kang Y, Perry RR. Effects of alpha-interferon on p-glycoprotein expression and function and on verapamil modulation of doxorubicin resistance. Cancer Res 1994;54:2952-8.
26. Johnson P, Allegra C. The interaction of 5-fluorouracil and cisplatin in human colon carcinoma cells [Abstract 2497]. Proc Am Assoc Cancer Res 1990;31:421.
27. Esaki T, Nakaho S, Tatsumoto T, et al. Inhibition by 5-fluorouracil of cis-diamminedichlorplastinum (11)-induced DNA interstrand cross-link removal in a HST-1 human squamous carcinoma. Cancer Res 1992;52:6501-6.
28. Scanlon KJ, Newman EM. Lu Y, Priest DG. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci U S A 1986;83:8923-5.
29. Cozzolino F, Torcia M, Lucibello M, et al. Interferon-alpha and interleukin 2 synergestically enhance basic fibroblast growth factor synthesis and induce release, promoting endothelial cell growth. J Clin Invest 1993;91:2504-12.
30. Ezekowitz RA, Mulliken JB, Folkman J. Interferon alpha-2 therapy for life-threatening hemangiomas of infancy (see comments; published erratum appears in N Engl J Med 1994;330:300]. N. Engl J Med 1992;326:1456-63.
31. Brouty-Boyé D, Zetter BR. Inhibition of cell motility by interferon. Science 1980;208:516-8.
32. Sidkey YA, Borden EC. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res 1987;47:5155-61.